

# CENTER FOR DRUG EVALUATION AND RESEARCH

## Approval Package for:

### *APPLICATION NUMBER:*

**213801Orig1s000**

*Trade Name:* MYRBETRIQ GRANULES, for extended-release oral suspension

*Generic or Proper Name:* mirabegron

*Sponsor:* Astellas Pharma Global Development, Inc.

*Approval Date:* March 25, 2021

*Indication:* treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older

# CENTER FOR DRUG EVALUATION AND RESEARCH

## 213801Orig1s000

### CONTENTS

<b>Reviews / Information Included in this NDA Review.</b>
---

<b>Approval Letter</b>	<b>X</b>
<b>Other Action Letters</b>	
<b>Labeling</b>	<b>X</b>
<b>REMS</b>	
<b>Summary Review</b>	<b>X</b>
<b>Officer/Employee List</b>	<b>X</b>
<b>Office Director Memo</b>	
<b>Cross Discipline Team Leader Review</b>	
<b>Clinical Review(s)</b>	<b>X</b>
<b>Product Quality Review(s)</b>	<b>X</b>
<b>Non-Clinical Review(s)</b>	<b>X</b>
<b>Statistical Review(s)</b>	<b>X</b>
<b>Clinical Microbiology / Virology Review(s)</b>	
<b>Clinical Pharmacology Review(s)</b>	<b>X</b>
<b>Other Reviews</b>	<b>X</b>
<b>Risk Assessment and Risk Mitigation Review(s)</b>	
<b>Proprietary Name Review(s)</b>	<b>X</b>
<b>Administrative/Correspondence Document(s)</b>	<b>X</b>

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**213801Orig1s000**

**APPROVAL LETTER**



NDA 213801

**NDA APPROVAL**

Astellas Pharma Global Development, Inc.  
Attention: Carol Soo  
Director, Regulatory Affairs  
1 Astellas Way  
Northbrook, IL 60062

Dear Ms. Soo:

Please refer to your new drug application (NDA) dated and received September 28, 2020, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Myrbetriq Granules (mirabegron extended-release for oral suspension), 8 mg/mL.

This new drug application provides for the use of Myrbetriq Granules (mirabegron for extended-release oral suspension), 8 mg/mL, for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older.

### **APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

### **WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS**

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Patient Package Insert, as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible via publicly available labeling repositories.

### **CARTON AND CONTAINER LABELING**

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved NDA 213801.**” Approval of this submission by FDA is not required before the labeling is used.

### **DATING PERIOD**

Based on the stability data submitted to date, the expiry dating period for Myrbetriq Granules (mirabegron extended-release for oral suspension) shall be 24 months from the date of manufacture when stored at 20°C to 25°C.

Results of ongoing stability should be submitted throughout the dating period in your annual report, as they become available, including the results of stability studies from the first three production lots.

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

This product is appropriately labeled for use in all relevant pediatric populations. Therefore, no additional pediatric studies are needed at this time.

### **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the

---

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs*.<sup>3</sup>

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.<sup>4</sup> Information and Instructions for completing the form can be found at FDA.gov.<sup>5</sup>

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Nenita Crisostomo, Regulatory Health Project Manager, at 301-796-0875.

Sincerely,

*{See appended electronic signature page}*

Christine P. Nguyen, M.D.  
Director  
Division of Urology, Obstetrics, and  
Gynecology  
Office of Rare Diseases, Pediatrics, Urologic  
and Reproductive Medicine  
Center for Drug Evaluation and Research

## **ENCLOSURES:**

- Content of Labeling
  - Prescribing Information
  - Patient Package Insert
- Carton and Container Labeling

---

<sup>3</sup> For the most recent version of a guidance, check the FDA guidance web page at

<https://www.fda.gov/media/128163/download>.

<sup>4</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

<sup>5</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

CHRISTINE P NGUYEN  
03/25/2021 03:52:26 PM